Rituximab (Mabthera) --new approach in treatment of rheumatoid arthritis
Anić, B.
Reumatizam 54(2): 72-73
2007
ISSN/ISBN: 0374-1338 PMID: 18351146 Document Number: 614223
Document emailed within 1 workday
Related Documents
Benucci, M.; Iannazzo, S.; Zaniolo, O.; Sabadini, L. 2010: Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis Clinical and Experimental Rheumatology 28(5): 722-727Yazici, Y.; McMorris, B.J.; Darkow, T.; Rosenblatt, L.C. 2009: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis Clinical and Experimental Rheumatology 27(6): 907-913
2015: Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties Prescrire International 24(161): 145-148
Tony, H.-P.; Roll, P.; Mei, H.E.; Blümner, E.; Straka, A.; Gnuegge, L.; Dörner, T. 2015: Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab Clinical and Experimental Rheumatology 33(6): 887-894
Mesihović-Dinarević, S.; Ibrahimović, J. 2005: Modern approach to treatment of juvenile rheumatoid arthritis Medicinski Arhiv 59(3): 196-198
Narvaez, J.; Díaz-Torné, C.; Ruiz, J.M.; Hernandez, M.V.; Torrente-Segarra, V.; Ros, S.; Rodriguez de la Serna, A.; Díaz-López, C.; Sanmartí, R.; Nolla, J.M. 2011: Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs Clinical and Experimental Rheumatology 29(6): 991-997
Suzuki, K.; Takeuchi, T. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Towards precision medicine in rheumatoid arthritis Clinical Calcium 28(5): 626-629
Yamanaka, H. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. how to use the guideline in the management of rheumatoid arthritis Clinical Calcium 28(5): 607-610
Yasuda, S. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis Clinical Calcium 28(5): 668-676
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Carr, A.J. 1996: Margaret Holroyd Prize Essay. A patient-centred approach to evaluation and treatment in rheumatoid arthritis: the development of a clinical tool to measure patient-perceived handicap British Journal of Rheumatology 35(10): 921-932
Sheir, Z.M.; Abdel-Razek, A.K.; Nagaty, M.; Amer, Z.M.; Refai, M.R. 1974: A clinico-radiological approach to the study of rheumatoid arthritis Journal of the Egyptian Medical Association 57(7-8): 275-287
Revaz, S.; Dudler, J. 2008: Diagnosis and treatment of rheumatoid vasculitis and other systemic complications of rheumatoid arthritis Revue Medicale Suisse 4(149): 712; 714 716-717
Smith, C.A.; Arnett, F.C. 1991: Epidemiologic aspects of rheumatoid arthritis. Current immunogenetic approach Clinical Orthopaedics and Related Research 265: 23-35
Langdon, C.G.; Moran, D.G.; Jamieson, V.; Spence, S.; Hill, S.A. 1990: A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice Journal of International Medical Research 18(6): 489-496
Marhoffer, W.; Schatz, H.; Stracke, H.; Ullmann, J.; Schmidt, K.; Federlin, K. 1991: Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis Journal of Rheumatology 18(8): 1158-1162
Henrard, J.C.; Bennett, P.H.; Burch, T.A. 1974: Epidemiology of rheumatoid arthritis. Evaluation of the so-called Rome and new York criteria for the diagnosis of rheumatoid arthritis in a population study Revue du Rhumatisme et des Maladies Osteo-Articulaires 41(11): 675-683
Barrera, P.; Balsa, A.; Alves, H.; Westhovens, R.; Maenaut, K.; Cornélis, F.; Fritz, P.; Bardin, T.; Ceu Maia, M.; Lopes-Vaz, A.; Pascual Salcedo, D.; de la Concha, E.; Radstake, T.; van de Putte, L.B.; Migliorini, P.; Prudhomme, J.F.; Charron, D.; Spyropoulou, M.; Mendes, A.; Spaepen, M.; Martinez, M.; Stavropoulos, C. 2001: Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF) Journal of Rheumatology 28(5): 968-974
Jaller Char, J.J.; Jaller, J.A.; Waibel, J.S.; Bhanusali, D.G.; Bhanusali, N. 2018: The Role of IL-17 in the Human Immune System and its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Journal of Drugs in Dermatology: Jdd 17(5): 539-542
Chen, J.R.; Takahashi, M.; Suzuki, M.; Kushida, K.; Miyamoto, S.; Inoue, T. 1998: Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis Journal of Rheumatology 25(12): 2440-2444